Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

LD-2 disclosure · 2nd Quarter - Report

QIAGEN, INC.

via MAYER BROWN LLP

2nd Quarter (Apr 1 - June 30) · 2013Posted Jul 19, 2013Filing document ↗LDA record ↗

Income$100Kfee reported

Client

Name: QIAGEN, INC.
Description: Biotechnology company
Location: Maryland · United States of America

Registrant

Firm: MAYER BROWN LLP
Description: Law firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
CMS reimbursement rates for molecular diagnostic tests.
LobbyistsTIFFANY L SMITH
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

QIAGEN, INC. — Lobbying — Receipts Report